Aligos Therapeutics (NASDAQ:ALGS) Announces Earnings Results

Aligos Therapeutics (NASDAQ:ALGS) posted its quarterly earnings results on Thursday. The company reported ($3.04) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($2.09) by ($0.95), Zacks reports. The company had revenue of $0.74 million during the quarter, compared to analysts’ expectations of $0.50 million. Aligos Therapeutics had a negative return on equity of 40.71% and a negative net margin of 3,267.65%.

Aligos Therapeutics Stock Down 0.4%

Shares of ALGS opened at $7.07 on Friday. The stock’s 50-day moving average price is $9.70 and its 200-day moving average price is $8.17. The company has a market capitalization of $43.48 million, a price-to-earnings ratio of -0.36 and a beta of 2.76. Aligos Therapeutics has a 52 week low of $3.76 and a 52 week high of $46.80.

Hedge Funds Weigh In On Aligos Therapeutics

Large investors have recently made changes to their positions in the company. XTX Topco Ltd acquired a new position in shares of Aligos Therapeutics in the second quarter worth about $100,000. Geode Capital Management LLC boosted its position in Aligos Therapeutics by 21.3% during the second quarter. Geode Capital Management LLC now owns 34,048 shares of the company’s stock worth $246,000 after purchasing an additional 5,978 shares in the last quarter. Vanguard Group Inc. grew its holdings in Aligos Therapeutics by 22.8% in the third quarter. Vanguard Group Inc. now owns 171,689 shares of the company’s stock valued at $1,683,000 after purchasing an additional 31,913 shares during the period. Finally, Woodline Partners LP purchased a new stake in shares of Aligos Therapeutics in the first quarter valued at approximately $2,602,000. 60.43% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

A number of brokerages recently issued reports on ALGS. Wall Street Zen lowered Aligos Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday. Weiss Ratings restated a “sell (d-)” rating on shares of Aligos Therapeutics in a research note on Wednesday, October 8th. Finally, HC Wainwright reiterated a “buy” rating and issued a $50.00 target price on shares of Aligos Therapeutics in a research report on Friday, September 12th. One investment analyst has rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, the company presently has a consensus rating of “Hold” and an average price target of $50.00.

About Aligos Therapeutics

Aligos Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development of novel therapeutics to address unmet medical needs in viral and liver diseases. Its drug candidate, ALG-055009, a small molecule THR-ß agonist that is in the Phase 2a clinical trial for the treatment of non-alcoholic steatohepatitis (NASH).